XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment information
9 Months Ended
Oct. 01, 2017
Segment Reporting [Abstract]  
Segment information
Note 14 — Segment information
The following tables present the Company’s segment results for the three and nine months ended October 1, 2017 and September 25, 2016:
 
Three Months Ended
 
Nine Months Ended
 
October 1, 2017
 
September 25, 2016
 
October 1, 2017
 
September 25, 2016
 
(Dollars in thousands)
 
(Dollars in thousands)
Revenue
 
 
 
 
 
 
 
Vascular North America
$
90,979

 
$
85,118

 
$
278,350

 
$
254,817

Anesthesia North America
50,819

 
48,670

 
148,107

 
143,821

Surgical North America
40,804

 
41,827

 
131,464

 
123,904

EMEA
131,517

 
121,398

 
394,212

 
375,198

Asia
72,387

 
64,087

 
185,328

 
176,434

OEM
48,589

 
41,418

 
137,067

 
115,693

All other
99,608

 
53,130

 
276,669

 
164,227

Consolidated net revenues
$
534,703

 
$
455,648

 
$
1,551,197

 
$
1,354,094

 
Three Months Ended
 
Nine Months Ended
 
October 1, 2017
 
September 25, 2016
 
October 1, 2017
 
September 25, 2016
 
(Dollars in thousands)
 
(Dollars in thousands)
Operating profit
 
 
 
 
 
 
 
Vascular North America
$
25,212

 
$
21,781

 
$
75,286

 
$
63,431

Anesthesia North America
15,684

 
13,954

 
49,727

 
41,181

Surgical North America
13,618

 
14,050

 
47,285

 
39,654

EMEA
24,187

 
16,576

 
69,677

 
61,563

Asia
20,217

 
18,072

 
49,619

 
52,831

OEM
12,256

 
10,201

 
31,714

 
24,605

All other
11,987

 
3,444

 
16,953

 
16,623

Total segment operating profit (1)
123,161

 
98,078

 
340,261

 
299,888

Unallocated expenses (2)
(12,807
)
 
(11,591
)
 
(58,886
)
 
(47,463
)
Income from continuing operations before interest, loss on extinguishment of debt and taxes
$
110,354

 
$
86,487

 
$
281,375

 
$
252,425

(1)
Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved.
(2)
Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.